Merck & Co., Inc. (NYSE:MRK), Insider Bruce Kuhlik unloaded 145,225 shares of Merck & Co. stock in a transaction dated Friday, April 4th. The shares were sold at an average price of $56.43, for a total value of $8,195,046.75. Following the transaction, the insider now directly owns 121,845 shares of the company’s stock, valued at approximately $6,875,713. The sale was disclosed in a filing with the SEC, which is available at this link. Merck & Co., Inc. (NYSE:MRK), shares after opening at $56.56 moved to $57.30 on last trade day and at the end of the day closed at $57.25. Company price to sales ratio in past twelve months was calculated as 3.82 and price to cash ratio as 9.63. Merck & Co., Inc. (NYSE:MRK), showed a positive weekly performance of 2.38%.
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)’s shares gained 5.72% to $8.04. The company on Mar. 24 announced the initiation of a pivotal global Phase 2 trial of AP26113 in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who were previously treated with crizotinib. The ALTA (ALK in Lung Cancer Trial of AP26113) trial is designed to determine the safety and efficacy of AP26113 in refractory NSCLC patients who test positive for the anaplastic lymphoma kinase (ALK+) oncogene. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), shares advanced 2.64% in last trading session and ended the day on $7.39. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), return on equity ratio is recorded as -98.50% and its return on assets is 65.80%. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), yearly performance is -60.48%.
Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA), has been given an average rating of “Buy” by the twenty-three analysts that are covering the stock, ARN reports. Nine equities research analysts have rated the stock with a hold recommendation, eight have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $54.66. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA), shares moved down 0.35% in last trading session and was closed at $50.67, while trading in range of $ 49.92 – 51.28. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA), year to date (YTD) performance is 27.38%.
On April 20,2014, UK-based Johnson & Johnson (NYSE:JNJ), Professional Export, a division of Johnson & Johnson Medical Ltd, is proud to celebrate the honor of winning the Queen’s Award for Enterprise. The award for ‘International Trade’ was given in recognition of their successful domestic and international strategies which have widened access to their extensive range of medical devices and diagnostic products in emerging markets including Iran, Malta/Gibraltar and Sub-Saharan Africa. Johnson & Johnson (NYSE:JNJ), weekly performance is 3.23%. On last trading day company shares ended up $100.00. Johnson & Johnson (NYSE:JNJ), distance from 50-day simple moving average (SMA50) is 5.98%. Analysts mean target Price for the company is $104.55.
Leave a Reply